Kevin Bitterman
InvestorPartner at Atlas Venture · Board director at Renasant Bio · Board director at Judo Bio · Director of the Issuer at Kinaset Therapeutics
Cambridge, Massachusetts
Writes $10M – $50M checks · typically $25M
Find your path to Kevin
283 people in our graph share verified history with Kevin — schools, employers, funds. One of them is your warm intro.
About
Kevin Bitterman invests in and helps build companies that turn scientific research into new medicines. He was the founding CEO of Editas Medicine, Morphic Therapeutic (acquired by Lilly), and Visterra (acquired by Otsuka), and joined Atlas Venture in 2017 after serving as a partner on the healthcare team at Polaris Partners since 2004. He holds a BA in biology from Rutgers University and a PhD in genetics from Harvard Medical School.
Contact· self-published, not guessed
Likely emails· guessed from name + firm domain, not firm-published
- k•••@atlasventure.comreveal100% confident
- k•••@atlasventure.comreveal90% confident
- k•••@atlasventure.comreveal75% confident
Invests in
Biotech
Board director at Renasant Bio
Intro paths
In turn, Kevin can intro founders to Renasant Bio's investors below.
Renasant Bio's investors · 4
Co-founders at Renasant Bio
Board director at Judo Bio
Intro paths
In turn, Kevin can intro founders to Judo Bio's investors below.
Judo Bio's investors · 5
Co-founders at Judo Bio
Director of the Issuer at Kinaset Therapeutics
Intro paths
In turn, Kevin can intro founders to Kinaset Therapeutics's investors below.
Kinaset Therapeutics's investors · 8
Co-founders at Kinaset Therapeutics
Experience
- Atlas VenturePartnercurrent2017 — presentCambridge, MA
- Judo BioBoard of Directorscurrent2022 — presentCambridge, Massachusetts, United States
- Remix TherapeuticsBoard of Directorscurrent2019 — presentCambridge, Massachusetts, United States
- nChroma BioBoard of Directorscurrent2020 — presentCambridge, Massachusetts, United States
- Kinaset TherapeuticsBoard of Directorscurrent2020 — presentBoston, Massachusetts, United States
- Disc MedicineBoard Of Directorscurrent2017 — presentCambridge, MA
- Isabella Stewart Gardner MuseumMember Board of Trusteescurrent2017 — presentBoston, Massachusetts, United States
- Mariana OncologyBoard of Directors2021 — 2024Cambridge, Massachusetts, United States
- New England Venture Capital AssociationBoard Member2013 — 2023Greater Boston Area
- Akero TherapeuticsBoard of Directors2018 — 2021Cambridge, MA
- Navitor PharmaceuticalsBoard of Directors2017 — 2020Cambridge, MA
- Editas MedicineBoard of Directors2014 — 2018Cambridge, MA
- Editas MedicineFounding CEO2013 — 2014Cambridge, MA
- Morphic TherapeuticBoard of Directors2015 — 2017Waltham, MA
- Morphic TherapeuticFounding CEO2014 — 2015Greater Boston Area
- Vets First ChoiceBoard of Directors2012 — 2017
- Neuronetics, Inc.Board of Directors2011 — 2017
- Polaris PartnersPartner2004 — 2017Greater Boston Area
- Kala PharmaceuticalsBoard of Directors2009 — 2017
- Taris BiomedicalBoard of Directors2008 — 2017
- Genocea BiosciencesBoard of Directors2006 — 2017
- Visterra Inc.Board of Directors2009 — 2015
Skills & more
+12 more
Cell BiologyStart-upsImmunologyVaccinesOncologyInfectious DiseasesDrug DevelopmentBiomarkersPharmaceutical IndustryFDARegulatory AffairsBiochemistryFrom Kevin's professional profile.
Deals · 9
Renasant BioBoard seat
via Atlas Venture · filed Jul 2025 · $30M raise
GrobioBoard seat
via Atlas Venture · filed Jul 2024 · $60.4M raise
Chroma Medicine, Inc.Board seat
via Atlas Venture · filed Sep 2023 · $135M raise
Navitor PharmaceuticalsBoard seat
via Atlas Venture · filed May 2020 · $20.2M raise
Akero Therapeutics, Inc.Board seat
via Atlas Venture · filed Dec 2018 · $45.5M raise
Morphic Holding, Inc.Board seat
via Atlas Venture · filed Jul 2016 · $51.5M raise
KALA BIOBoard seat
via Atlas Venture · filed Aug 2015 · $7M raise
Direct Vet MarketingBoard seat
via Atlas Venture · filed Jul 2015 · $52.3M raise
NeuroneticsBoard seat
via Atlas Venture · filed May 2015 · $34.3M raise
Attribution from SEC filings, press coverage, and firm rosters.
Other disclosed investments
Board seats
Akero TherapeuticsDisc MedicineJudo BioKinaset TherapeuticsKinaset TherapeuticsMariana OncologynChroma BioRemix TherapeuticsRemix Therapeutics
Investor
Akero TherapeuticsArsenal MedicalBiolex TherapeuticsCurie TherapeuticsDisc MedicineFollicaGenocea BiosciencesGRO BiosciencesJudo BioMariana OncologyMorphic TherapeuticPulmatrixRemix TherapeuticsVets First ChoiceVisterra
Sources: the firm's website · SEC Form D filings · curated public sources.
Colleagues at Atlas Venture
Network1
Investors connected to Kevin in public investor directories — a warm-intro map.
Frequently asked questions
- Who is Kevin Bitterman?
- Kevin Bitterman invests in and helps build companies that turn scientific research into new medicines. He was the founding CEO of Editas Medicine, Morphic Therapeutic (acquired by Lilly), and Visterra (acquired by Otsuka), and joined Atlas Venture in 2017 after serving as a partner on the healthcare team at Polaris Partners since 2004. He holds a BA in biology from Rutgers University and a PhD in genetics from Harvard Medical School.
- Where does Kevin Bitterman work?
- Kevin Bitterman is Partner at Atlas Venture and Board director at Renasant Bio and Board director at Judo Bio and Director of the Issuer at Kinaset Therapeutics.
- What does Kevin Bitterman invest in?
- Kevin Bitterman invests in Biotech.
- What check size does Kevin Bitterman write?
- Kevin Bitterman typically writes checks of $10M – $50M.
- What boards does Kevin Bitterman sit on?
- Kevin Bitterman holds tracked board seats at Akero Therapeutics, Akero Therapeutics, Inc., Chroma Medicine, Inc., Direct Vet Marketing, Disc Medicine, Grobio, Judo Bio, KALA BIO, Kinaset Therapeutics, Kinaset Therapeutics.
- What companies has Kevin Bitterman invested in?
- Investments tracked here include Akero Therapeutics, Arsenal Medical, Biolex Therapeutics, Curie Therapeutics, Disc Medicine, Follica, Genocea Biosciences, GRO Biosciences, Judo Bio, KALA BIO, Mariana Oncology, Morphic Therapeutic, and 6 more.
- Where did Kevin Bitterman go to school?
- Kevin Bitterman studied at Harvard Medical School (Ph.D., Genetics); Rutgers University (BA, Biology).
Founder mafias
Harvard Medical School mafia111
Also came through, then founded or led a company.
+ 104 more
Rutgers University mafia100
Also came through, then founded or led a company.
+ 93 more
Atlas Venture mafia21
Also came through, then founded or led a company.
+ 14 more
Polaris Partners mafia5
Also came through, then founded or led a company.
Grobio mafia3
Also came through, then founded or led a company.
Same school
Also attended Harvard Medical School331
+ 325 more
Also attended Rutgers University307
+ 301 more
